Respiratory syncytial virus
A common respiratory virus causing severe illness in infants and the elderly.
Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a negative-sense, single-stranded RNA virus that causes infections of the respiratory tract. Its name derives from the large, multinucleated cells known as syncytia that form when infected cells fuse. RSV is a common cause of respiratory hospitalization in infants and a notable pathogen in all age groups, with reinfection common throughout life.
- type
- Negative-sense, single-stranded RNA virus
- genus
- Orthopneumovirus
- family
- Pneumoviridae
- order
- Mononegavirales
- known_for
- Leading cause of bronchiolitis in infants and severe respiratory illness in older adults and immunocompromised individuals
Lore & Background
Chanock identified the same virus in children with respiratory illness. Studies of human antibodies in infants and children revealed that the infection was common in early life. The virus was later renamed human orthopneumovirus, or human respiratory syncytial virus (hRSV). Several other pneumoviruses show great similarity to hRSV; bovine RSV shares approximately 80% of its genome with hRSV and causes similar disease in calves, making it an important animal model for RSV research.
Reader's Guide
Respiratory syncytial virus is a significant global pathogen, particularly affecting infants, older adults, and immunocompromised individuals. Nearly all children in the United States experience at least one RSV infection before two years of age, and it is responsible for about 70% of bronchiolitis cases. In adults, reinfection is common but usually mild, though the elderly and those with underlying conditions face higher risks of pneumonia and death. The virus can cause outbreaks in both community and hospital settings. Prophylactic monoclonal antibodies (palivizumab or nirsevimab) can prevent infection in high-risk infants. Treatment for severe illness is primarily supportive, including oxygen therapy and mechanical ventilation if needed. The virus's transmission via respiratory aerosols suggests airborne precautions may be necessary for reliable protection.
Did You Know?
- The virus's name comes from the large, multinucleated cells (syncytia) that form when infected cells fuse.
- Bovine RSV shares about 80% of its genome with human RSV and causes similar disease in calves, serving as an important animal model.
Droplet-Borne Spread as RSV's Primary Vector
RSV is classified among the respiratory viruses that travel primarily through droplet transmission. This means the virus is expelled when an infected person coughs, sneezes, or even talks, producing particles larger than five micrometers. Unlike truly airborne pathogens such as tuberculosis or measles, RSV droplets are too large to linger in the air for extended periods. They fall to the ground or onto nearby surfaces within a short distance, making close proximity the key risk factor. The virus can land directly on the eyes, nose, or mouth of a susceptible person, or it can settle on a surface and later be transferred when someone touches their face with contaminated hands. This short-range, contact-adjacent behavior is what distinguishes RSV from the more elusive airborne threats and shapes how healthcare settings and households approach its containment.
Prevention Strategies Tailored to Droplet Physics
Because RSV travels in relatively large droplets rather than as tiny aerosol nuclei, the infection-control strategies that apply differ markedly from those used for measles or tuberculosis. Negative-pressure rooms and dedicated ventilation systems, while critical for airborne pathogens, are not the primary defense against RSV. Instead, the emphasis falls on reducing the emission of droplets at the source—wearing a surgical mask over the nose and mouth of an infected person is cited as a practical way to cut down the volume of respiratory particles released during coughing, sneezing, or conversation. Equally important is breaking the indirect chain: frequent hand-washing and disinfection of shared surfaces interrupt the fomite pathway by which the virus reaches the eyes, nose, or mouth of a new host. In settings where children congregate, these simple mechanical barriers become the backbone of outbreak prevention, since the virus cannot sustain itself in the air long enough to require the more elaborate engineering controls reserved for true airborne diseases.
Pediatric Vulnerability and the Challenge of Community Transmission
RSV occupies a particularly troubling position in pediatric public health, and the routes by which it spreads compound that vulnerability. In addition to the familiar droplet pathway, the fecal-oral route—transmission through unwashed hands, contaminated food, or poor water and sanitation—carries outsized weight in young children and in developing regions where hygiene infrastructure is limited. This dual exposure means that even in households with careful respiratory etiquette, a toddler can pick up the virus from a contaminated toy, a shared cup, or a caregiver's hands after handling a diaper. When the source of infection cannot be traced to a specific contact or travel link, the situation is classified as community transmission, a label that signals the virus is circulating invisibly within a population. For epidemiologists, the difficulty of mapping each chain of spread in dense, mobile communities makes RSV one of the hardest pediatric pathogens to contain, especially where clean water access and sanitation remain inconsistent.
The 2024 WHO Terminology Overhaul and Its Policy Gap
The new framework, aligned with particle physics, replaces older, sometimes overlapping language with four precise categories: airborne transmission, inhalation, direct deposition, and contact. Under this scheme, RSV's characteristic short-range droplet spread and surface-mediated transfer would be captured more accurately than under the older labels that blurred the distinction between particles that remain suspended and those that simply fall. However, as of the time of reporting, these refined definitions have not yet been woven into actionable policy. Infection-control guidelines, the pandemic accords, and the updated International Health Regulations still rely on the previous terminology, leaving a gap between the scientific precision now available and the operational language that hospitals, public-health agencies, and international bodies actually use to protect populations from RSV and its respiratory peers.
Frequently Asked Questions
What is Respiratory Syncytial Virus?
RSV is a single-stranded, negative-sense RNA virus in the Pneumoviridae family that specifically targets the respiratory tract. It got its name from the giant multinucleated cells—called syncytia—that form when infected airway cells fuse together.
What does RSV do in the body?
It invades the epithelial lining of the airways, triggering inflammation, excess mucus, and narrowing of the passages. In young infants this most often presents as bronchiolitis, while in older or immunocompromised adults it can escalate to severe pneumonia.
How does an RSV infection typically end?
Most healthy adults clear the virus within one to two weeks with only mild, cold-like symptoms. In infants and the elderly the illness can persist longer and sometimes demand hospital-level respiratory support, and because sterilizing immunity is never achieved, reinfection is expected throughout life.
Why is RSV considered such a significant pathogen?
It is the leading viral cause of bronchiolitis in babies under one year and a top driver of respiratory hospitalizations in adults over sixty. Because reinfection is common and lasting immunity does not develop, it remains a persistent public-health burden across every age group.
More in Microbial Pathogens 1-20
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record
